Panitumumab for the treatment of metastatic colorectal cancer

Abstract

The introduction of novel, targeted therapies has improved the treatment options available to patients with metastatic colorectal cancer. Panitumumab (Vectibix) is the first fully human monoclonal antibody to be licensed in this setting and offers an effective and well-tolerated therapy for patients with tumours expressing wild-type KRAS.